Extended Delivery Pharmaceuticals, LLC (EDP) is a development stage biotechnology company developing a long acting form of Insulin.
More than 285 million people worldwide have diabetes. The World Health Organization (WHO) projects that deaths from diabetes will double by 2030. WHO estimates that direct expenditures for diabetes therapy to exceed 418 billion “International Dollars” in 2010.
Insulin is used in the treatment of diabetes for millions of people. Currently used forms of insulin however force patients to perform daily, sometimes multiple daily injections to control glucose levels. It is widely believed that longer acting insulin formulations can lead to improved patient compliance with therapeutic regimes and ultimately better health overall.
One injection of EDP’s lead drug candidate, SIA-II insulin has demonstrated tight glucose control for 140+ days in established diabetic animal models. Secondary complications usually associated with diabetes were also significantly reduced in SIA-II treated animals. This data has recently been published in Proceedings of the National Academy of Sciences of the USA.
EDP is developing SIA-II in the USA and internationally. Our hope is to ultimately improve the prognosis of diabetes patients world-wide.